Lymecycline
Clinical data | |
---|---|
Trade names | Tetralysal |
AHFS/Drugs.com | International Drug Names |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 100% (oral) |
Elimination half-life | 10 hours |
Excretion | Kidney |
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Lymecycline is a
soluble than tetracycline base and is unique amongst tetracyclines in that it is absorbed by an active transport process across the intestinal wall, making use of the same fast and efficient mechanism by which carbohydrates are absorbed.[1]
The greater absorption of lymecycline allows for lower dosages to be used; the standard dose of 408 mg is equivalent to 300 mg tetracycline base and, in its action, to 500 mg tetracycline hydrochloride. Lymecycline, unlike tetracycline hydrochloride, is soluble at all
physiological pH values.[citation needed
]
History
Lymecycline was introduced by Farmitalia in 1963.[citation needed]
Indications
Lymecycline, like other tetracyclines, is used to treat a range of infections.
Acne
Its better absorption profile makes it preferable to tetracycline for moderately severe
acne and typically prescribed for 8 weeks at a time, but alternatives should be sought if no improvement occurs by 3 months.[2]
Side effects
Lymecycline's side effects can include
reflux oesophagitis.[3] Recently, the family of tetracycline antibiotics has been associated with thyroid dysfunction in youth.[4]
See also
References
- ^ New Zealand Datasheet Archived 2006-03-03 at the Wayback Machine August 2003
- ^ British National Formulary 45 March 2003
- ^ Wang P. "Side effects of Tetralysal". Retrieved 23 March 2011.
- PMID 27059913.